About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis

BridgeBio Pharma (NASDAQ: BBIO), a leading biopharmaceutical company, announced significant outcomes from the ATTRibute-CM, their Phase 3 study of acoramidis, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Superior Efficacy of Acoramidis Shown in Clinical Trial

The trial recorded a highly statistically significant improvement in the primary endpoint with a Win Ratio of 1.8 (p<0.0001). A meaningful separation was observed across all measures of mortality, morbidity, function, and quality of life. An impressive 81% on-treatment survival rate was achieved as opposed to a 74% survival rate on placebo. Notably, the risk of cardiovascular-related hospitalization was reduced by a significant 50% (p<0.0001) with the acoramidis treatment.

Secondary Endpoints Demonstrate Consistent Treatment Benefit

Treatment benefits were also observed in secondary endpoints such as NT-proBNP, KCCQ, and 6-minute walk distance, all of which showed a highly significant and clinically meaningful improvement at 30 months (p<0.0001).

Comparative Analysis Supports Promising Outcomes of Acoramidis

Post hoc comparative analysis showed that acoramidis resulted in a 42% greater increase in serum TTR levels and a 92% improvement in median NT-proBNP relative to placebo + tafamidis.

Safety and NDA Filing

No safety signals of clinical concern were identified during the trial. Further enhancing the significance of these results, BridgeBio intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2023.

Acoramidis Paves the Way for Future Treatment

The ATTRibute-CM trial’s positive results offer new hope for patients with ATTR-CM. As per Dr. Daniel Judge, co-chair of the ATTRibute-CM Steering Committee, the results are truly remarkable. The robust findings confirm the potential of potent TTR stabilization to impact patients’ lives significantly. Acoramidis shows promise as a potent, orally-administered, small molecule stabilizer of transthyretin, positioning BridgeBio at the forefront of genetic diseases and cancers treatment research.

BridgeBio’s Continued Commitment to Research and Development

The filing of the NDA is part of the company’s commitment to develop medicines that target diseases at their source, reflecting BridgeBio’s overall portfolio strategy. Acoramidis has intellectual property protection until at least 2039, ensuring its long-term potential as a groundbreaking treatment option.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.